Abstract 247P
Background
Immune checkpoint inhibitors (ICIs) have shown survival benefits in multiple clinical trials in patients with lung cancer. To gain further insights into real-world treatment patterns of lung cancer patients treated with ICIs, we performed a multicenter study.
Methods
We analyzed anonymized electronic health records from ten different data sources in three Belgian hospitals in a cohort of lung cancer patients treated with ICIs between March 2017 and August 2022. A total of 597 variables were analyzed, mapped to SNOMED-CT, and OMOP-CDM databases were created. We utilized machine learning and natural language processing (NLP) to process records and algorithm outputs were validated against a physician-generated standard.
Results
We detected 731 lung cancer patients with a mean (SD) age of 67 (10) years and predominantly male (67%). Smoking status was: current, 47.7%; former, 25.9%; never, 8.6%; unknown, 17.8%. The most common ICI treatment (monotherapy or with other ICIs or antineoplastic drugs) was pembrolizumab (62.4%), followed by nivolumab (15.4%), atezolizumab (12.4%), and durvalumab (9.4%). Within the patients with available performance status (PS; n = 405, 55.4%), 21.5% had PS 0, 56.3% had PS 1, 10.7% had PS 2, and 1.6% had PS 3-4. Lung cancer was metastatic in 60.6% of patients, non-metastatic in 22.7%, and of unknown status for 16.7%. Preliminary analyses show a median overall survival (OS, 95% confidence intervals) of 30 (26, 35) months across all lung cancers and types of therapies.
Conclusions
These preliminary results demonstrate the feasibility of autonomously extracting and locally validating federated hospital databases—a crucial tool for accessing real-world data on patients with lung cancer receiving ICI treatment. Analyses focusing on immune-related adverse events, comorbidities, tumor stage, anatomical pathology, and treatment lines and histology are ongoing.
Legal entity responsible for the study
LynxCare Clinical Informatics.
Funding
LynxCare Clinical Informatics.
Disclosure
All authors have declared no conflicts of interest.